Medicare Enrolled
Dr. Niloo Prasad, MD
Hematology & Oncology · Edison, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Prasad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Prasad?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Prasad
Dr. Niloo Prasad is a hematology & oncology specialist in Edison, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Prasad performed 2,462 Medicare services across 453 unique beneficiaries.
Between the years covered by Open Payments, Dr. Prasad received a total of $7,032 from 50 pharmaceutical and/or device companies across 405 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Prasad is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 44% volume in NJ
$7,032 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,462
Medicare services
Top 44% in NJ for hematology & oncology
453
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~130 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
600 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
461 | $8 | $18 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
435 | $101 | $231 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
412 | $7 | $32 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
143 | $27 | $132 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
131 | $12 | $83 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
85 | $103 | $231 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
66 | $57 | $272 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
42 | $1 | $6 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
41 | $1 | $14 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
31 | $66 | $152 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $127 | $354 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
8.5% high complexity
31.4% medium
60.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,032
Total received (2018-2024)
Avg $1,005/year across 7 years
Top 34% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
405
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,018 (85.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,014 (14.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,260
2023
$1,368
2022
$1,454
2021
$655
2020
$863
2019
$811
2018
$622
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$180
SEAGEN INC.
$99
Janssen Biotech, Inc.
$99
Eisai Inc.
$81
AstraZeneca Pharmaceuticals LP
$72
Regeneron Healthcare Solutions, Inc.
$67
Lilly USA, LLC
$65
Gilead Sciences, Inc.
$64
Bayer Healthcare Pharmaceuticals Inc.
$55
Incyte Corporation
$47
Daiichi Sankyo Inc.
$46
ARRAY BIOPHARMA INC
$38
Novartis Pharmaceuticals Corporation
$33
PUMA BIOTECHNOLOGY, INC.
$32
EMD Serono, Inc.
$32
TAIHO ONCOLOGY, INC.
$32
Acrotech Biopharma Inc.
$30
Dendreon Pharmaceuticals LLC
$19
Lundbeck LLC
$19
Tempus AI, Inc
$19
Takeda Pharmaceuticals U.S.A., Inc.
$18
Blueprint Medicines Corporation
$18
SERVIER PHARMACEUTICALS LLC
$16
Pharmacosmos Therapeutics Inc.
$16
Genentech USA, Inc.
$16
Exelixis Inc.
$16
GlaxoSmithKline, LLC.
$15
Astellas Pharma US Inc
$14
Top 3 companies account for 30.0% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$1,233
Janssen Biotech, Inc.
$960
E.R. Squibb & Sons, L.L.C.
$444
Novartis Pharmaceuticals Corporation
$350
Astellas Pharma US Inc
$347
Celgene Corporation
$319
Gilead Sciences, Inc.
$296
Daiichi Sankyo Inc.
$283
PFIZER INC.
$250
Merck Sharp & Dohme Corporation
$246
AstraZeneca Pharmaceuticals LP
$225
Eisai Inc.
$162
Lilly USA, LLC
$134
Incyte Corporation
$132
Seagen Inc.
$122
AVEO Pharmaceuticals, Inc.
$119
Exelixis Inc.
$104
Regeneron Healthcare Solutions, Inc.
$102
SEAGEN INC.
$99
ARRAY BIOPHARMA INC
$92
Genentech USA, Inc.
$81
Bayer HealthCare Pharmaceuticals Inc.
$73
Adaptive Biotechnologies Corporation
$72
Bayer Healthcare Pharmaceuticals Inc.
$71
GlaxoSmithKline, LLC.
$57
TESARO, Inc.
$56
EMD Serono, Inc.
$48
Takeda Pharmaceuticals U.S.A., Inc.
$46
ABBVIE INC.
$44
PUMA BIOTECHNOLOGY, INC.
$32
TAIHO ONCOLOGY, INC.
$32
Dendreon Pharmaceuticals LLC
$32
GENZYME CORPORATION
$31
Acrotech Biopharma Inc.
$30
Pharmacosmos Therapeutics Inc.
$30
Coherus Biosciences Inc.
$27
TOLMAR Pharmaceuticals, Inc.
$27
Rigel Pharmaceuticals, Inc.
$26
Global Blood Therapeutics, Inc.
$24
Lundbeck LLC
$19
Tempus AI, Inc
$19
Blueprint Medicines Corporation
$18
Apellis Pharmaceuticals, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$16
Foundation Medicine, Inc.
$16
Dova Pharmaceuticals
$15
Merck Sharp & Dohme LLC
$15
Heron Therapeutics, Inc.
$14
Acceleron Pharma, Inc.
$14
Karyopharm Therapeutics Inc.
$13
Top 3 companies account for 37.5% of all-time payments
Associated products mentioned in payments ›
ALIMTA · AYVAKIT · Aliqopa · Avastin · BAVENCIO · BOSULIF · BRAFTOVI · Blincyto · CABOMETYX · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMEND · ENHERTU · ERLEADA · Empaveli · Enhertu · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · GAZYVA · IBRANCE · ICLUSIG · IMBRUVICA · INJECTAFER · INLYTA · JADENU · JAKAFI · JEMPERLI · KANJINTI · KEYTRUDA · KISQALI · KISUNLA · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONOFERRIC · NINLARO · Neulasta · Nplate · Nubeqa · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · PADCEV · PIQRAY · PROMACTA · PROVENGE · Padcev · Pomalyst · Prolia · REBLOZYL · RYBREVANT · RYZNEUTA · Reblozyl · Revlimid · SCEMBLIX · SUSTOL · Stivarga · TABRECTA · TAGRISSO · TALVEY · TASIGNA · TECVAYLI · TUKYSA · Tavalisse · Tibsovo · Trodelvy · Udenyca · VENCLEXTA · VERZENIO · VYEPTI · Venclexta · XALKORI · XGEVA · XPOVIO · XT CDX · XTANDI · Xtandi · ZEJULA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
433
Per 100K population
50.3
County median income
$109,028
Nearest hospital
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL AT RAHWAY
4.9 mi
4.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Prasad is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Prasad experienced with dexamethasone injection (steroid)?
Based on Medicare claims data, Dr. Prasad performed 600 dexamethasone injection (steroid) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Prasad receive payments from pharmaceutical companies?
Yes. Dr. Prasad received a total of $7,032 from 50 companies across 405 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Prasad's costs compare to other hematology & oncology specialists in Edison?
Dr. Prasad's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Prasad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Edison
Browse hematology & oncology specialists in Edison ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology